Sign in
Taking peopleNo phase

Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye

Key facts

Who runs it
Zhongshan Ophthalmic Center, Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
3,000 people, planned
Started
12 Dec 2023
Expected to end
Dec 2028
Type of study
Observational, 2 groups
Treatments tested
  • Smartphone-based on-device artificial intelligence system for anterior segment eye disease screening
Record updated
9 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Willing to participate and able to provide written informed consent prior to enrollment

Who cannot take part

  • Unable to cooperate with anterior segment image capture (including smartphone-based photography or slit-lamp biomicroscopy)

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening. The system is designed to identify 16 clinically important anterior segment conditions from images captured using a standard Android smartphone. A core design feature of the system is that all image analysis is performed entirely on the smartphone itself, without requiring internet connectivity or cloud-based server infrastructure.

Read full original descriptionShow less

The study is motivated by a structural challenge in the deployment of medical AI: systems that depend on cloud infrastructure for inference are non-functional in settings without reliable internet access, which disproportionately excludes populations in low-resource regions where the burden of preventable eye disease is highest. This study evaluates whether an on-device AI system, designed with operational constraints as a primary engineering objective, can deliver clinically acceptable diagnostic performance while remaining operable under real-world connectivity limitations.

The study comprises five evaluation components. First, the diagnostic performance of the AI system is benchmarked against board-certified ophthalmologists of varying seniority on a standardized set of smartphone-captured anterior segment images. Second, the usability of the system is evaluated among non-medical users who perform self-administered screening with minimal instruction, with per-screening time recorded across consecutive attempts to characterize the learning curve. Third, a head-to-head field trial directly compares the on-device AI system against a functionally equivalent cloud-based deployment of the same model architecture across key operational dimensions including screening duration, diagnostic performance, and user acceptability. Fourth, population-level screening is conducted among consecutively enrolled community residents at two low-resource sites, with per-disease sensitivity and specificity calculated against reference-standard slit-lamp examinations. Fifth, pre-specified health-economic and environmental analyses compare the two deployment modalities in terms of per-person screening cost, cost-effectiveness, per-inference electricity consumption, and projected carbon emissions at scale.

The reference standard for all diagnostic comparisons is slit-lamp biomicroscopic examination performed by board-certified ophthalmologists. The study is designed and reported in accordance with the DECIDE-AI reporting guideline for early-stage clinical evaluation of AI-driven decision-support systems.

The 2 groups in the trial

  • On-Device Deployment Group

    Participants screened using a smartphone-based AI system that performs all image inference locally on the device without requiring internet connectivity. The AI system analyzes smartphone-captured anterior segment images and generates diagnostic outputs entirely on the smartphone hardware, independent of cloud infrastructure or network access.

    Treatment: Smartphone-based on-device artificial intelligence system for anterior segment eye disease screening

  • Cloud-Based Deployment Group

    Participants screened using a functionally equivalent deployment of the same AI model architecture, in which smartphone-captured anterior segment images are transmitted to a remote server for inference, with diagnostic outputs returned via internet connection. This group serves as the comparator to evaluate the operational differences attributable solely to deployment modality, as the underlying model architecture is identical between the two groups.

    Treatment: Smartphone-based on-device artificial intelligence system for anterior segment eye disease screening

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
9 June 2026